Pharmacology
-
Effects of LAMA or ICS withdrawal may increase risk for COPD exacerbations
Discontinuing LAMA or ICS treatment may more than double the risk of exacerbations for up to 90 days, according to an analysis by Alexander Mathioudakis, MD, PhD.
-
Biologic therapies in asthma: From foundation to the future
Biologic therapies are changing severe asthma management, shifting the goal from control to remission. Diego J. Maselli, MD, FCCP; Dharani Narendra, MD, FCCP; and Megan Conroy, MD, MAEd, FCCP, explore their impact in this installment of Clinical Outlook in Pulmonology.
-
Sotatercept in pulmonary arterial hypertension
Understanding when to consider sotatercept and how to use it has become a critical part of PAH care.
-
GLP-1RAs may trigger chronic cough for some patients with diabetes
Surprisingly, the association between GLP-1 medications and chronic cough was stronger in patients without an existing diagnosis of gastroesophageal reflux disease.
-
GLP-1RAs may reduce risk of asthma exacerbations for adolescents with obesity
Pulmonologist Farrukh Abbas, MD, said this observational study generates a hypothesis about the anti-inflammatory benefits of GLP1-RA medications in patients with asthma and obesity that needs to be confirmed in trials.
-
Third trial supports sotatercept to treat PAH
Guidelines expert James R. Klinger, MD, FCCP, said that while the evidence of efficacy is clear, more research is needed to address questions regarding the optimal duration of therapy and the potential for disease progression if therapy is stopped.
-
Oseltamivir found to lower risk of flu-linked neuropsychiatric events in children
This study is the largest and most comprehensive US investigation of the drug and severe neuropsychiatric events, said author James Antoon, MD, PhD, MPH.
-
Experts evaluate treatment of PAH in the sotatercept era
Zeenat Safdar, MD, FCCP, reviewed recent clinical trial data on the use of the activin-signaling inhibitor sotatercept in pulmonary arterial hypertension (PAH).
-
Osimertinib plus chemo beat chemo alone in patients with advanced EGFR-mutated NSCLC who advanced on first-line osimertinib
Experts said the results of the COMPEL trial support continued treatment with osimertinib beyond progression in this patient population.
-
Multidisciplinary panel highlights considerations for GLP-1 agonist use in OSA
Chitra Lal, MD, FCCP, discussed the current indications and coverage criteria for use of tirzepatide for treatment of OSA, as well as possible roles for other GLP-1 agonists.
